INTRODUCTION: Breast cancer is the first cause of cancer death in women. The triple-negative subtype is associated with aggressive behavior and poor prognosis. Chemotherapy is the main therapeutic option available for these patients, but it is usually associated with short overall survival. CASE PRESENTATION: We report the case of a patient diagnosed with metastatic triple-negative breast cancer with an impressive long-lasting tumor response and long-term survival after pembrolizumab monotherapy. CONCLUSION: Immunotherapy is emerging as a promising treatment for some breast cancer patients. Nevertheless, monotherapy studies have shown a very limited activity. Nowadays, there is no good predictor biomarker. Further investigations are needed to identify the subgroup of patients who can benefit from checkpoint inhibitor treatment.
INTRODUCTION: Breast cancer is the first cause of cancer death in women. The triple-negative subtype is associated with aggressive behavior and poor prognosis. Chemotherapy is the main therapeutic option available for these patients, but it is usually associated with short overall survival. CASE PRESENTATION: We report the case of a patient diagnosed with metastatic triple-negative breast cancer with an impressive long-lasting tumor response and long-term survival after pembrolizumab monotherapy. CONCLUSION: Immunotherapy is emerging as a promising treatment for some breast cancer patients. Nevertheless, monotherapy studies have shown a very limited activity. Nowadays, there is no good predictor biomarker. Further investigations are needed to identify the subgroup of patients who can benefit from checkpoint inhibitor treatment.
Authors: S Adams; P Schmid; H S Rugo; E P Winer; D Loirat; A Awada; D W Cescon; H Iwata; M Campone; R Nanda; R Hui; G Curigliano; D Toppmeyer; J O'Shaughnessy; S Loi; S Paluch-Shimon; A R Tan; D Card; J Zhao; V Karantza; J Cortés Journal: Ann Oncol Date: 2019-03-01 Impact factor: 32.976
Authors: E Borcoman; Y Kanjanapan; S Champiat; S Kato; V Servois; R Kurzrock; S Goel; P Bedard; C Le Tourneau Journal: Ann Oncol Date: 2019-03-01 Impact factor: 32.976
Authors: Peter Schmid; Sylvia Adams; Hope S Rugo; Andreas Schneeweiss; Carlos H Barrios; Hiroji Iwata; Véronique Diéras; Roberto Hegg; Seock-Ah Im; Gail Shaw Wright; Volkmar Henschel; Luciana Molinero; Stephen Y Chui; Roel Funke; Amreen Husain; Eric P Winer; Sherene Loi; Leisha A Emens Journal: N Engl J Med Date: 2018-10-20 Impact factor: 91.245
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Sylvia Adams; Robert J Gray; Sandra Demaria; Lori Goldstein; Edith A Perez; Lawrence N Shulman; Silvana Martino; Molin Wang; Vicky E Jones; Thomas J Saphner; Antonio C Wolff; William C Wood; Nancy E Davidson; George W Sledge; Joseph A Sparano; Sunil S Badve Journal: J Clin Oncol Date: 2014-09-20 Impact factor: 44.544
Authors: Luc Y Dirix; Istvan Takacs; Guy Jerusalem; Petros Nikolinakos; Hendrik-Tobias Arkenau; Andres Forero-Torres; Ralph Boccia; Marc E Lippman; Robert Somer; Martin Smakal; Leisha A Emens; Borys Hrinczenko; William Edenfield; Jayne Gurtler; Anja von Heydebreck; Hans Juergen Grote; Kevin Chin; Erika P Hamilton Journal: Breast Cancer Res Treat Date: 2017-10-23 Impact factor: 4.872